E Fund Management Co. Ltd. Invests $1.42 Million in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

E Fund Management Co. Ltd. bought a new position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 189,432 shares of the company’s stock, valued at approximately $1,421,000.

Other institutional investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD acquired a new position in Kyverna Therapeutics during the first quarter worth $23,093,000. Jennison Associates LLC acquired a new position in Kyverna Therapeutics during the first quarter worth $34,743,000. Janus Henderson Group PLC acquired a new position in Kyverna Therapeutics during the first quarter worth $15,041,000. TD Asset Management Inc acquired a new position in Kyverna Therapeutics during the second quarter worth $677,000. Finally, Vanguard Group Inc. acquired a new position in Kyverna Therapeutics during the first quarter worth $6,563,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Kyverna Therapeutics Stock Performance

KYTX stock opened at $6.66 on Wednesday. The company’s 50-day simple moving average is $8.06 and its 200 day simple moving average is $13.97. Kyverna Therapeutics, Inc. has a 52 week low of $6.30 and a 52 week high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.03. As a group, analysts anticipate that Kyverna Therapeutics, Inc. will post -3.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on KYTX. JPMorgan Chase & Co. lowered their target price on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. HC Wainwright decreased their price objective on shares of Kyverna Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Thursday, August 15th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.40.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.